JoVE Logo

Sign In

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be maladaptive, exacerbating fluid retention and worsening heart failure symptoms. One such mechanism involves activating the renin-angiotensin-aldosterone system (RAAS), which leads to vasoconstriction and further fluid retention.

Diuretics have been a mainstay in managing fluid overload in heart failure patients. They work by inhibiting sodium reabsorption in the nephrons, increasing urine output, and reducing fluid overload. Loop diuretics, thiazide diuretics, and potassium-sparing diuretics are commonly used, each with unique mechanisms of action. Loop diuretics act on the thick ascending limb of the loop of Henle, blocking the sodium-potassium-chloride cotransporter. Thiazide diuretics work on the distal convoluted tubule, inhibiting the sodium-chloride symporter. Potassium-sparing diuretics inhibit sodium reabsorption in the collecting ducts while sparing potassium. Aldosterone or mineralocorticoid receptor antagonists (MRAs) like spironolactone and eplerenone are combined with diuretics. These MRAs inhibit the action of aldosterone, a hormone that promotes sodium retention and potassium excretion. By blocking this action, MRAs promote sodium excretion and potassium retention, aiding in fluid balance.

However, the use of diuretics has limitations. Overuse can lead to electrolyte imbalances, particularly hypokalemia and renal dysfunction. Also, diuretic resistance is a phenomenon in which the body becomes less responsive to diuretics over time. This underscores the need to monitor and manage diuretics in heart failure patients carefully.

Tags
Heart FailureDiureticsRenal PerfusionFluid BalanceNeurohumoral MechanismsRAASLoop DiureticsThiazide DiureticsPotassium sparing DiureticsAldosterone AntagonistsElectrolyte ImbalancesDiuretic ResistanceFluid OverloadSodium Reabsorption

From Chapter 10:

article

Now Playing

10.10 : Heart Failure Drugs: Diuretics

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

157 Views

article

10.1 : Electrophysiology of Normal Cardiac Rhythm

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

733 Views

article

10.2 : Mechanism of Cardiac Arrhythmias

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

654 Views

article

10.3 : Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

721 Views

article

10.4 : Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

525 Views

article

10.5 : Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

619 Views

article

10.6 : Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

516 Views

article

10.7 : Pathophysiology of Cardiac Performance

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

294 Views

article

10.8 : Pathophysiology of Heart Failure

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

1.1K Views

article

10.9 : Heart Failure Drugs: Inotropic Agents

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

213 Views

article

10.11 : Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

167 Views

article

10.12 : Heart Failure Drugs: β-Blockers

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

128 Views

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved